Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant Neoplasms
|
1641 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.050 | 0.600 | 5 | 2011 | 2017 | |||||
Primary malignant neoplasm
|
1374 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.040 | 0.750 | 4 | 2011 | 2017 | |||||
Carcinoma, Ovarian Epithelial
|
327 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.030 | 1.000 | 3 | 2010 | 2011 | |||||
Colorectal Carcinoma
|
1962 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.030 | 1.000 | 3 | 2014 | 2017 | |||||
Malignant neoplasm of ovary
|
315 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.030 | 1.000 | 3 | 2010 | 2011 | |||||
ovarian neoplasm
|
757 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.030 | 1.000 | 3 | 2010 | 2011 | |||||
Breast Carcinoma
|
2793 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 0.500 | 2 | 2012 | 2016 | |||||
Endometriosis
|
274 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 0.500 | 2 | 2012 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 0.500 | 2 | 2012 | 2016 | |||||
Neoplasm Metastasis
|
327 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 1.000 | 2 | 2016 | 2016 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 1.000 | 2 | 2011 | 2015 | |||||
Squamous cell carcinoma of the head and neck
|
348 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.020 | 1.000 | 2 | 2014 | 2016 | |||||
Breast Cancer, Familial
|
91 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1 | 2012 | 2012 | ||||||
Dry skin
|
12 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Epithelial ovarian cancer
|
129 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Gallbladder Carcinoma
|
75 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Hereditary Breast and Ovarian Cancer Syndrome
|
2117 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Malignant neoplasm of gallbladder
|
81 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Malignant neoplasm of soft tissue
|
32 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Myeloid Leukemia, Chronic
|
115 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Sarcoma
|
42 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Secondary malignant neoplasm of colon and/or rectum
|
68 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Skin toxicity
|
24 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.662 | 0.320 | 12 | 25207290 | 3 prime UTR variant | A/C | snv | 6.2E-02 | 0.010 | 1.000 | 1 | 2016 | 2016 |